Personalized mRNA Vaccines for Cancer Patients

Vision: To deliver personalized precision (n=1) mRNA cancer vaccine immunotherapies for Cancer Patients in the UK, in cooperation with the NHS, with MHRA “specials” license.

Our Mission

To help cancer patients. In the UK to consistently beat the “mean survival” for their cancer, with our 2 core products.

To Beat Cancer. Cancer will emerge in 1 of 2 people within their lifetime. Cancer is a tragic disease which causes pain, misery and death. Cancer costs the UK Government and Society over £15 billion per annum.

Targeted

Normax UK investigational mRNA cancer vaccines will be manufactured for individuals based on the specific molecular features of their tumors which are called neoantigens. Training your immune system to recognize these neoantigen protein targets on the surface of your cancer cells could empower your body to control your cancer.

Personalized

For more than a decade, cancer researchers have been developing a type of treatment known as a personalized cancer vaccine using various technologies, including mRNA and protein fragments, or peptides to target your neoantigens of your cancer. A personalized mRNA vaccine from Normax UK could be a safe and effective tool for your doctors to use in the arsenal to fight your cancer.

Rapid Delivery

Normax UK plans to produce a personalized mRNA cancer vaccine for you, after tissue samples have been collected, within 1 to 2 months. Speed is especially important for individualized cancer vaccination. Ideally, a highly individualized vaccine combination to target your neoantigens should be designed and produced within 10 weeks of taking your tumor biopsy and blood sample.

Partnership with MTIF

Our mission is to provide a bridge between Academia and Commercial Industry, to enable the acceleration of innovative Medical Technologies. MTIF strives to help our clients improve the quality of patient care and create a lasting legacy in Healthcare.

The Collaboration

“We are delighted to announce our new collaboration with Normax Biomed Limited to offer access to the BioXP 3250 system from Telesis Bio at our Research Facility to accelerate the development and discovery of new mRNA vaccines and gene therapies.”

mRNA CANCER VACCINE TECHNOLOGY

Step 1

Identifying the unique mutations of your cancer by comparing the differences of the DNA sequences of your cancer cells and your normal cells.

Step 2

Selecting and testing the patient cancer mutations that could his natural immune system to launch the most effective attack on the cancer cells.

Step 3

Using mRNA vaccine technology to produce the personalized cancer vaccine

mRNA CANCER VACCINE TECHNOLOGY

Clinical Trials

Normax UK is initiating clinical trial testing of personalized mRNA vaccines to target individual neoantigens. The goal is a complete and enduring response whereby all signs of the tumor disappear following treatment.

Advanced AI Analytics

The manufacturing process starts with the identification of genetic mutations in a patient’s tumor cells that could give rise to neoantigens. Computer algorithms then predict which neoantigens are most likely to bind to receptors on T cells and stimulate an immune response.

T Cell Education

The vaccine can include genetic sequences for many different neoantigens. The promise of personalized immunotherapy with mRNA vaccines is being able to activate T cells that will specifically recognize individual cancer cells based on their abnormal molecular features.

The Problem: Cancer in the UK

Cancer Prevalence in the UK

2023

0
people living with cancer

2025

0
people living with cancer

2030

0
people living with cancer

2040

0
people living with cancer

Cancer

Incidence

2019

0
diagnosed with cancer

Cancer

Deaths

YEARLY

0
cancer deaths in UK

Cancer

Oncologists

2020

0
full-time clinical oncologists

Cancer

Patients

2020

0
patients per clinical oncologist

Cancer Economic Cost in UK

YEARLY

£ 0
full-time clinical oncologists

NHS Waiting List

2023

0
patients on the waiting list

Discover The Future of Personalized Precision Cancer Immunotherapy